Literature DB >> 8717386

DNA-based immunization against the envelope proteins of the hepatitis B virus.

M Mancini1, H Davis, P Tiollais, M L Michel.   

Abstract

Intramuscular injection in mice of DNA expression vectors encoding the envelope proteins of the hepatitis B virus induced humoral responses specific to several antigenic determinants of the viral envelope. The use of different promoter elements in the plasmid vectors influenced the kinetics and specificity of antibodies produced to the envelope proteins. The first antibodies appeared within 1-2 weeks after injection of DNA and included antibodies of the IgM isotype. Over the following weeks, an IgM-to-IgG class switch occurred, indicating helper T-lymphocyte activity. Peak IgG titers were reached by 4 weeks after a single DNA injection and were maintained for at least 6 months without further DNA injections. The antibodies to the envelope proteins reacted with both group- and subtype-specific antigenic determinants of the HBV surface antigen (HBsAg). The nature of the immune response to the envelope proteins provides indirect evidence that the proteins have adopted a native conformation and have probably been assembled into particles after intramuscular expression from the plasmid vectors. These results indicate that it may be possible to rationally design DNA expression vectors to induce a particular type of immune response for vaccination against hepatitis B or other pathogens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8717386     DOI: 10.1016/0168-1656(95)00098-4

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  7 in total

1.  CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.

Authors:  E Malanchère-Brès; P J Payette; M Mancini; P Tiollais; H L Davis; M L Michel
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV.

Authors:  Jing Jin; Jian-Ying Yang; Jing Liu; Yu-Ying Kong; Yuan Wang; Guang-Di Li
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

3.  Characterization of the specific CD4+ T cell response against the F protein during chronic hepatitis C virus infection.

Authors:  De-Yong Gao; Gen-Di Jin; Bi-Lian Yao; Dong-Hua Zhang; Lei-Lei Gu; Zhi-Meng Lu; Qiming Gong; Yu-Chun Lone; Qiang Deng; Xin-Xin Zhang
Journal:  PLoS One       Date:  2010-12-06       Impact factor: 3.240

4.  Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.

Authors:  D Marsac; D Loirat; C Petit; O Schwartz; M-L Michel
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

5.  Hepatitis B virus splice-generated protein induces T-cell responses in HLA-transgenic mice and hepatitis B virus-infected patients.

Authors:  Maryline Mancini-Bourgine; Florence Bayard; Patrick Soussan; Qiang Deng; Yu-Chun Lone; Dina Kremsdorf; Marie-Louise Michel
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

6.  Targeted screening of SiRNA directed HBV polymerase gene for effective inhibition of HBV expression.

Authors:  Jinjian Yao; Weiling Yu; Ying Chang; Jinghua Ren; Dong Xu; Siyuan Han; Jusheng Lin
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-06-19

Review 7.  The state of gene therapy research in Africa, its significance and implications for the future.

Authors:  P Arbuthnot; M B Maepa; A Ely; M S Pepper
Journal:  Gene Ther       Date:  2017-07-10       Impact factor: 5.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.